Similar articles

• Clinical experience with vaccines produced in the human diploid cell line WI-38.

  Andzaparidze OG. Andzaparidze OG. Natl Cancer Inst Monogr. 1968 Dec;29:477-84. Natl Cancer Inst Monogr. 1968. PMID: 4976367 Clinical Trial. No abstract available.
• Characteristics of primary cultures and diploid cells--technology of production.

  Holper JC. Holper JC. Natl Cancer Inst Monogr. 1968 Dec;29:21-31. Natl Cancer Inst Monogr. 1968. PMID: 4976359 Review. No abstract available.
• Evidence for oncogenic properties of heteroploid cell lines--discussion.

  Moore AE. Moore AE. Natl Cancer Inst Monogr. 1968 Dec;29:291-2. Natl Cancer Inst Monogr. 1968. PMID: 4890060 Clinical Trial. No abstract available.
• Vaccines produced in diploid cell lines--discussion.

  Perkins FT. Perkins FT. Natl Cancer Inst Monogr. 1968 Dec;29:495-7. Natl Cancer Inst Monogr. 1968. PMID: 5720803 No abstract available.
• Virus-associated gain and loss of proliferative and neoplastic properties of normal and virus-transformed diploid cell lines.

  Yerganian G, Nell MA, Cho SS, Hayford AH, Ho T. Yerganian G, et al. Natl Cancer Inst Monogr. 1968 Dec;29:241-68. Natl Cancer Inst Monogr. 1968. PMID: 4306757 Review. No abstract available.